| Name | Title | Contact Details |
|---|
At Averitas Pharma, we strive to enable people with pain to live and feel more like their true selves. With patients at the forefront of every decision we make, we want more than to envision people not limited by their pain; we work every day with passion and determination to make it a reality. We are currently helping patients by offering the only FDA-approved, non-opioid, topical system for the treatment of neuropathic pain associated with postherpetic neuralgia (post-shingles nerve pain) and for neuropathic pain associated with diabetic peripheral neuropathy of the feet (diabetic nerve pain of the feet). We are proudly building on the 75-year legacy of Grünenthal, a global privately held healthcare company that has been working tirelessly toward a world free of pain by approaching pain as a disease in urgent need of a solution, rather than a mere symptom. We do it because we care. Most of us have either dealt with chronic pain or know someone who has, because it is a burden that far too many people around the world must bear. Our empathy for patients, and our shared sense of mission and purpose, are what inspires us to keep going. And our people are the key to our success. For more information, visit www.averitaspharma.com Community Guidelines: 1. We reserve the right to remove profanity, threatening or harassing content, promotional content and any personal information. 2. Due to FDA fair balance rules, we ask that you not mention any medicines or FDA-approved therapies by name or include links to third-party sites. 3. This site is not a forum for reporting side effects experienced while using an Averitas product. Physicians, other healthcare providers, and patients are encouraged to voluntarily report adverse events involving drugs or medical devices. To make a report you can visit www.fda.gov/medwatch or call 1-800-FDA-1088 For questions about our products call 1-877-900-6479. For more information, ask your healthcare provider or pharmacist.
Segetis is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eyenovia is a clinical stage, biopharmaceutical company transforming the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia`s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics.
Rapid Micro Biosystems accelerates the detection of microbial contamination in the manufacture of pharmaceuticals, biologics, medical devices, and personal care products. The company`s Growth Direct™ Platform—the first and only growth-based platform to fully automate traditional microbial testing—detects contamination more quickly, delivering compelling economic benefits while improving quality control processes. The Growth Direct platform replaces slow, error-prone, manual processes, allowing manufacturers to accelerate timelines, maximize capacity, and reduce operational risk and downtime, all while maintaining the highest standards of data integrity. Rapid Micro Biosystems is dedicated to providing groundbreaking technology and products to support biomanufacturing companies in their mission to deliver the highest possible quality products for improved patient outcomes. Rapid Micro Biosystems is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Germany and the Netherlands.
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWounds first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Companys lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWounds pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com